

Financial results for the quarter and nine months ended 31 December 2012

Part I		Rs in lakhs (except for number of shares)					
SI No.	Particulars	3 months ended 31/12/2012	3 months ended 30/09/2012	3 months ended 31/12/2011	9 months ended 31/12/2012	9 months ended 31/12/2011	Previous year ended 31/03/2012
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Income from operations						
	a) Net sales/ income from operations (net of excise duty)	10,491.39	9,922.82	15,348.33	29,540.29	43,958.99	53,127.97
	b) Other operating income	2.49	4.88	3.88	10.16	14.35	24.05
	Total income from operations (net)	10,493.88	9,927.70	15,352.21	29,550.45	43,973.34	53,152.02
2	Expenses						
	(a) Cost of materials consumed	947.74	1,379.29	1,349.33	3,042.88	5,742.23	7,151.68
	(b) Purchase of stock-in-trade	3,071.44	2,429.15	5,320.28	8,124.13	11,088.85	11,923.13
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	20.06	563.69	(1,941.87)	1,035.99	(3,426.54)	(1,210.38)
	(d) Employee benefits expense	3,965.48	3,859.01	3,523.09	11,164.04	10,400.15	16,191.24
	(e) Depreciation and amortisation expense	254.01	250.31	188.81	679.46	552.83	733.86
	(f) Other expenses	4,026.31	3,701.78	4,859.03	11,652.51	12,226.29	16,070.05
	Total expenses	12,285.04	12,183.23	13,298.67	35,699.01	36,583.81	50,859.58
3	Profit/ (loss) from operations before other income, finance costs and exceptional items (1-2)	(1,791.16)	(2,255.53)	2,053.54	(6,148.56)	7,389.53	2,292.44
4	Other income	21.63	173.92	146.44	979.08	431.63	633.04
5	Profit/ (loss) from ordinary activities before finance costs and exceptional items (3+4)	(1,769.53)	(2,081.61)	2,199.98	(5,169.48)	7,821.16	2,925.48
6	Finance costs	-	-	-	-	-	-
7	Profit/ (loss) from ordinary activities after finance costs but before exceptional items (5-6)	(1,769.53)	(2,081.61)	2,199.98	(5,169.48)	7,821.16	2,925.48
8	Exceptional items	-	-	-	-	-	-
9	Profit/ (loss) from ordinary activities before tax (7+8)	(1,769.53)	(2,081.61)	2,199.98	(5,169.48)	7,821.16	2,925.48
10	Tax expense	-	2,429.97	706.24	1,926.23	2,544.20	948.97
11	Net profit/(loss) from ordinary activities after tax (9-10)	(1,769.53)	(4,511.58)	1,493.74	(7,095.71)	5,276.96	1,976.51
12	Extraordinary Item	-	-	-	-	-	-
13	Net profit/(loss) for the period (11-12)	(1,769.53)	(4,511.58)	1,493.74	(7,095.71)	5,276.96	1,976.51
14	Paid-up equity share capital (Face value of Rs 2 per equity share)	500.00	500.00	500.00	500.00	500.00	500.00
15	Reserves excluding revaluation reserves as per the balance sheet of previous accounting year						18,428.52
16	Basic and diluted earnings (Rs) per share (not annualised)	(7.08)	(18.05)	5.97	(28.38)	21.11	7.91
	See accompanying notes to the financial results						
Part II							
A	Particulars of shareholding						
1	Public shareholding						
	- Number of shares	2,500,050	2,500,050	2,500,050	2,500,050	2,500,050	2,500,050
	- Percentage of shareholding	10.0002%	10.0002%	10.0002%	10.0002%	10.0002%	10.0002%
2	Promoters and promoter group shareholding						
	a) Pledged/Encumbered						
	- Number of shares	-	-	-	-	-	-
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-	-	-
	- Percentage of shares (as a % of the total share capital of the Company)	-	-	-	-	-	-
	b) Non-encumbered						
	- Number of shares	22,499,950	22,499,950	22,499,950	22,499,950	22,499,950	22,499,950
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%	100%
	- Percentage of shares (as a % of the total share capital of the Company)	89.9998%	89.9998%	89.9998%	89.9998%	89.9998%	89.9998%
B.	Particulars			3 months ended 31/12/2012			
	Investor complaints						
	Pending at the beginning of the quarter			Nil			
	Received during the quarter			8			
	Disposed of during the quarter			8			
	Remaining unresolved at the end of the quarter			Nil			

Notes:

- The above statement of financial results was reviewed by the Audit Committee and having been recommended for approval, was approved by the Board of Directors of the Company at their meeting held on 06 February 2013.
- The Company's sole reportable business segment is 'Healthcare'. The other segments are not material and are hence disclosed as 'Others'. Others comprise service income pertaining to clinical trials and co-promotion activities.
- Other income for the nine months period ended 31 December 2012 includes an amount of Rs 693.49 lakhs towards compensation for factory land acquired by National Highway Authority of India in the previous year.
- At the end of the previous financial year, the factory experienced interruptions to the supply of certain products. While several products have been returned to the market, the Company continues to pursue a remediation plan to address these interruptions. As a result of these interruptions, revenues and the financial results for the current quarter and nine months period ended 31 December 2012 are lower compared to the prior year. In January 2013, the factory experienced a further interruption in production which is under process of remediation.
- In view of the inadequacy of profit during the current period, the remuneration paid to the Managing Director up to 31 August 2012 (date of his resignation) and that paid/ payable to the Whole Time Director is subject to compliance with the requirements of Schedule XIII to the Companies Act, 1956
- Tax expense represents deferred tax assets amounting to Rs 2,429.97 lacs which have been charged to the profit and loss for the quarter ended 30 September 2012.
- The above statement of financial results have been reviewed by the statutory auditors. The statutory auditors have issued an unqualified review report. The review report has been filed with the stock exchange and is also available on the company's website.

**By Order of the Board of Directors
For AstraZeneca Pharma India Limited**

Bangalore
Dated: 06 February 2013

Ruby Lau
Whole Time Director

Segment wise revenue, results and capital employed

Sl.no.	Particulars	(Rs in lakhs)					
		3 months ended 31/12/2012	3 months ended 30/09/2012	3 months ended 31/12/2011	9 months ended 31/12/2012	9 months ended 31/12/2011	Previous year ended 31/03/2012
1	Segment revenue						
	(a) Healthcare	9,463.99	9,259.78	14,520.43	27,051.19	41,674.09	49,977.92
	(b) Others	1,029.89	667.92	831.78	2,499.26	2,299.25	3,174.10
	Total	10,493.88	9,927.70	15,352.21	29,550.45	43,973.34	53,152.02
	Less: Inter-segment revenue	-	-	-	-	-	-
	Net income from operations	10,493.88	9,927.70	15,352.21	29,550.45	43,973.34	53,152.02
2	Segment results						
	Profit/(loss) before tax and interest						
	(a) Healthcare	(2,003.34)	(2,306.31)	2,047.27	(6,387.90)	7,287.85	2,165.28
	(b) Others	212.18	50.78	6.27	239.34	101.68	127.16
	Total	(1,791.16)	(2,255.53)	2,053.54	(6,148.56)	7,389.53	2,292.44
	Add: Other income	21.63	173.92	146.44	979.08	431.63	633.04
	Less: Interest	-	-	-	-	-	-
	Total profit/(loss) before tax	(1,769.53)	(2,081.61)	2,199.98	(5,169.48)	7,821.16	2,925.48
3	Capital employed						
	(a) Healthcare	8,217.69	9,279.12	15,527.13	8,217.69	15,527.13	11,722.25
	(b) Others	184.81	454.42	562.23	184.81	562.23	817.67
	(c) Unallocated	3,430.31	3,868.80	7,156.55	3,430.31	7,156.55	6,388.60
	Total	11,832.81	13,602.34	23,245.91	11,832.81	23,245.91	18,928.52

Notes :

1 Certain assets and liabilities of the Healthcare segment are interchangeably used for other segments for limited purposes. Identification of such assets and liabilities is not feasible. Hence, such assets have not been allocated to any segment.